Product logins

Find logins to all Clarivate products below.


Icotrokinra

Learn how icotrokinra is changing the plaque psoriasis landscape.

What is icotrokinra and what sets it apart

If approved, icotrokinra will be the first-to-market targeted oral peptide designed to block the interleukin (IL)-23 receptor, which plays a key role in the inflammatory process in moderate-to-severe plaque psoriasis as well as ulcerative colitis.

Further validation of top-line phase 3 data could quickly establish icotrokinra in the psoriasis market as a first-line treatment, potentially preceding injectable biologics. As a result, icotrokinra is positioned to transform psoriasis care, providing an effective non-injectable option that meets long-standing patient demand for convenience without sacrificing efficacy.

About icotrokinra

  • Company: Johnson & Johnson
  • Type: IL-23 receptor antagonist
  • Usage: Once-daily oral administration to treat plaque psoriasis
    Also being evaluated to treat psoriatic arthritis and ulcerative colitis
  • When will icotrokinra be available?
    Expected launch 2026: United States
    Expected launch 2027: European Union, Japan

Icotrokinra sales and success forecasts

$1.5bn
expected sales in the G7 markets in 2031
95%
probability of success for icotrokinra in the United States

I consider icotrokinra to be the most promising oral drug in development. It appears to be highly effective with few side effects. It could replace biological agents such as TNF-α inhibitors or secukinumab.

Dermatologist Japan

Drugs in the 2026 list